The preliminary results of the authors’ clinical observations indicate that dogs with DLBCL and with high TOPIIα expression respond better to anthracycline-based therapy, which is manifested by a higher percentage of complete remission and a longer remission compared to dogs with DLBCL and low TOPIIα expression. This evidence concerns the gene TOP2A and diffuse large B-cell lymphoma.